PIK3CA and neoplasm: The first PI3K inhibitor to be clinically approved was idelalisib, a PI3Kδ-specific inhibitor that showed anti-tumor activity alone in relapsed indolent lymphoma, or in combination with rituximab (CD20 inhibitor) in chronic lymphocytic leukemia [5,10,52].